1. Academic Validation
  2. Identification of Benzofuro[2,3- b]pyridine Pseudonatural Product as a Novel Class of Ferritinophagy Inhibitors that Potently Suppress Ferroptosis

Identification of Benzofuro[2,3- b]pyridine Pseudonatural Product as a Novel Class of Ferritinophagy Inhibitors that Potently Suppress Ferroptosis

  • J Med Chem. 2025 Sep 11;68(17):18703-18726. doi: 10.1021/acs.jmedchem.5c01942.
Jiawei Zhang 1 Nanxuan Luo 1 Yijie Xiao 1 Zhangshun Luo 1 Lijie Lv 1 Jia Zheng 1 Jie Li 1 Xuan Li 1 Zhe-Yang Hu 2 Jian Min 2 Yahui Zhao 1 Yi He 1 Shenyou Nie 1 Hai-Xin Yuan 1 3
Affiliations

Affiliations

  • 1 Basic Medicine Research and Innovation Center for Novel Target and Therapeutic Intervention (Ministry of Education), Department of Urology and Department of Cancer Center of the Second Affiliated Hospital, College of Pharmacy, Chongqing Medical University, Chongqing 400016, China.
  • 2 School of Life Sciences, Hubei University, Wuhan 430072, China.
  • 3 The Fifth People's Hospital of Shanghai, Fudan University, Shanghai 200032, China.
Abstract

Ferroptosis is a form of regulated cell death mediated by iron-dependent phospholipid peroxidation. Pharmacological inhibition of Ferroptosis has been considered a promising therapeutic approach for various diseases. In this study, by integrating pseudonatural concepts with our newly developed rhodium-catalyzed C-H activation/Lossen rearrangement/oxa-Michael addition methodology, we rapidly assembled diverse benzofuro[2,3-b]pyridine PNP derivatives and systematically evaluated their antiferroptotic activity. Among these compounds, 4k exhibited significant activity in suppressing Ferroptosis. We further elucidated that 4k acts as a novel and specific inhibitor of ferritinophagy by targeting NCOA4 and disrupting its interaction with ferritin. Subsequent results demonstrated that 4k effectively ameliorated ConA-induced acute liver injury. Collectively, our findings indicate that 4k, featuring benzofuro[2,3-b]pyridine PNP scaffolds, acts as a selective inhibitor and could serve as a potential lead compound for further research. This work suggests that pharmacological targeting of the NCOA4-FTH1 interaction represents a promising intervention strategy for ferroptosis-related diseases.

Figures
Products